SG Americas Securities LLC grew its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA – Free Report) by 40.6% during the second quarter, according to its most recent SEC filing. The institutional investor owns 59,635 shares of the biotech company’s stock after purchasing an additional 17,222 shares during the period. SG Americas Securities LLC held 0.28% of Enanta Pharmaceuticals’ shares worth $1,276,000 as of the most recent SEC filing.
A number of other institutional investors have also increased or reduced their holdings in ENTA. BlackRock Inc. increased its holdings in shares of Enanta Pharmaceuticals by 0.6% in the first quarter. BlackRock Inc. now owns 3,776,402 shares of the biotech company’s stock valued at $152,718,000, after purchasing an additional 22,278 shares during the period. Armistice Capital LLC increased its holdings in Enanta Pharmaceuticals by 0.3% during the fourth quarter. Armistice Capital LLC now owns 2,078,000 shares of the biotech company’s stock valued at $96,669,000, after purchasing an additional 6,000 shares during the period. State Street Corp raised its holdings in shares of Enanta Pharmaceuticals by 29.9% during the second quarter. State Street now owns 1,699,428 shares of the biotech company’s stock valued at $80,332,000 after purchasing an additional 390,842 shares during the last quarter. Braidwell LP grew its position in Enanta Pharmaceuticals by 218.7% during the first quarter. Braidwell LP now owns 1,038,310 shares of the biotech company’s stock valued at $41,989,000 after purchasing an additional 712,472 shares during the last quarter. Finally, Krensavage Asset Management LLC purchased a new position in Enanta Pharmaceuticals during the first quarter worth approximately $24,397,000. Hedge funds and other institutional investors own 94.99% of the company’s shares.
Wall Street analysts forecast growth
Several research analysts have recently commented on ENTA stock. HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, September 19th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, September 11th. Royal Bank of Canada reiterated a “sector perform” rating and set a $25.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, August 8th. Oppenheimer lowered their target price on shares of Enanta Pharmaceuticals from $30.00 to $25.00 and set a “market perform” rating for the company in a research report on Wednesday, August 9th. Finally, JMP Securities lowered their target price on Enanta Pharmaceuticals from $65.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $38.50.
Check out our latest research report on ENTA
Enanta Pharmaceuticals rose 0.7%
Nasdaq ENTA opened at $11.89 on Friday. The stock has a 50-day moving average of $15.86 and a 200-day moving average of $25.67. Enanta Pharmaceuticals, Inc. has a 1-year low of $11.56 and a 1-year high of $62.06. The company has a market capitalization of $250.34 million, a P/E ratio of -1.88, and a beta value of 0.41.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report ) last announced its quarterly earnings results on Monday, August 7th. The biotech company reported ($1.86) earnings per share for the quarter, topping consensus estimates of ($2.38) by $0.52. The business had revenue of $18.89 million in the quarter, compared with analysts’ expectations of $15.88 million. Enanta Pharmaceuticals had a net profit margin of negative 163.87% and a return on equity of 46.77%. As a group, equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -7.24 earnings per share for the current fiscal year.
About Enanta Pharmaceuticals
(free report)
Enanta Pharmaceuticals, Inc is a biotechnology company that discovers and develops small molecule drugs to treat viral infections and liver diseases. Its R&D disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus and hepatitis B virus. The company has a collaborative development and licensing agreement with Abbott Laboratories to identify, develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
You can also take a look
Want to see what other hedge funds hold ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider transactions for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report).
This breaking news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team before publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enanta Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to clients every day. MarketBeat identified five stocks that top analysts were quietly whispering to clients to buy before the pandemic hit… and Enanta Pharmaceuticals wasn’t on the list.
While Enanta Pharmaceuticals currently has an analyst rating of “Hold”, these five stocks are considered better buys by analysts with the highest ratings.
Check out five stocks here
Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term prospects are very positive.
Get this free report